Herpes simplex genitalis antiviral treatment of first episode genital herpes: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Removing from Primary care)
 
(15 intermediate revisions by 5 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Herpes simplex}}
{{Herpes simplex}}
{{CMG}}; {{AE}} [[Lakshmi Gopalakrishnan, M.B.B.S.]]
{{CMG}}; {{AE}} {{YD}}, [[Lakshmi Gopalakrishnan, M.B.B.S.]]
==Overview==
==Overview==
Newly acquired genital herpes can cause a prolonged clinical illness with severe genital ulcerations and neurologic involvement. Patients with first-episode herpes who have mild clinical manifestations initially can develop severe or prolonged symptoms. Therefore, all patients with first episodes of genital herpes should receive antiviral therapy.
All patients with a first-episode [[genital herpes]] require [[Antimicrobial drug|antimicrobial therapy]]. Medical therapies for first-episode genital herpes include either oral [[acyclovir]], oral [[famciclovir]], or oral [[valacyclovir]]. Intravenous antiviral agents may be administered among patients with severe first-episode genital herpes.  
==Principles of Management of Genital Herpes<ref name="pmid16888612">Centers for Disease Control and Prevention. Workowski KA, Berman SM (2006) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=16888612 Sexually transmitted diseases treatment guidelines, 2006.] ''MMWR Recomm Rep'' 55 (RR-11):1-94. PMID: [http://pubmed.gov/16888612 16888612]</ref>==
==Medical Therapy==
*Antiviral chemotherapy offers clinical benefits to the majority of symptomatic patients and is the mainstay of management.
*All patients with a first-episode genital herpes require antimicrobial therapy.<ref name="pmid26042815">{{cite journal| author=Workowski KA, Bolan GA, Centers for Disease Control and Prevention| title=Sexually transmitted diseases treatment guidelines, 2015. | journal=MMWR Recomm Rep | year= 2015 | volume= 64 | issue= RR-03 | pages= 1-137 | pmid=26042815 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26042815  }} </ref>
*Systemic antiviral drugs can partially control the signs and symptoms of herpes episodes when used to treat first clinical episodes and recurrent episodes or when used as daily suppressive therapy. However, these drugs neither eradicate latent virus nor affect the risk, frequency, or severity of recurrences after the drug is discontinued.
*Treatment aims to manage present lesions but not cure the disease or prevent future occurrences.
*[[Antiviral]] [[chemotherapy]] offers clinical benefits to the majority of symptomatic patients and is the mainstay of management.
*Topical therapy with antiviral drugs offers minimal clinical benefit, and its use is discouraged.
*Topical therapy with antiviral drugs offers minimal clinical benefit, and its use is discouraged.
==First Clinical Episode of Genital Herpes<ref name="pmid16888612">Centers for Disease Control and Prevention. Workowski KA, Berman SM (2006) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=16888612 Sexually transmitted diseases treatment guidelines, 2006.] ''MMWR Recomm Rep'' 55 (RR-11):1-94. PMID: [http://pubmed.gov/16888612 16888612]</ref>==
===First Clinical Episode of Genital Herpes===
*Many patients with first-episode herpes have mild clinical manifestations but later develop severe or prolonged symptoms. Therefore, patients with initial genital herpes should receive antiviral therapy.
====Symptomatic Management====
*General advice:
*Many patients with first-episode herpes have mild clinical manifestations, but they are often predisposed to developing severe or prolonged symptoms.
*Symptomatic therapy includes the following:<ref name="pmid26042815">{{cite journal| author=Workowski KA, Bolan GA, Centers for Disease Control and Prevention| title=Sexually transmitted diseases treatment guidelines, 2015. | journal=MMWR Recomm Rep | year= 2015 | volume= 64 | issue= RR-03 | pages= 1-137 | pmid=26042815 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26042815  }} </ref>
:*Saline bathing
:*Saline bathing
:*[[Analgesia]]
:*[[Analgesia]]
:*Topical anaesthetic agents such as [[Lidocaine|5% lidocaine]] ointment may be useful to apply especially prior to [[micturition]] but should be used with caution because of the risk of potential sensitization.
:*Topical anaesthetic agents such as [[Lidocaine|5% lidocaine]] ointment may be applied prior to [[micturition]] (risk of potential sensitization)
====Antimicrobial Therapy====
*1. '''Mild/Moderate genital HSV infection'''<ref name="pmid26042815">{{cite journal| author=Workowski KA, Bolan GA, Centers for Disease Control and Prevention| title=Sexually transmitted diseases treatment guidelines, 2015. | journal=MMWR Recomm Rep | year= 2015 | volume= 64 | issue= RR-03 | pages= 1-137 | pmid=26042815 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26042815  }} </ref>
:*1.1. '''First episode of genital herpes'''
::* Preferred regimen: [[Acyclovir]] 400 mg PO tid for 7–10 days {{or}} [[Acyclovir]] 200 mg PO five times a day for 7–10 days {{or}} [[Famciclovir]] 250 mg PO tid for 7–10 days {{or}} [[Valacyclovir]] 1 g PO bid for 7–10 days
:::* Note (1): Treatment can be extended if healing is incomplete after 10 days of therapy
:::* Note (2): Dose-adjustment is often necessary among patients with impaired renal function
*2. '''Severe genital HSV infection'''
:*2.1. '''First episode of genital herpes'''
::*Preferred regimen: [[Acyclovir]] 5-10 mg/kg IV q8h for 2-7 days or until clinical improvement {{then}} ([[Acyclovir]] 400 mg PO tid for at least 10 days {{or}} [[Acyclovir]] 200 mg PO five times a day for at least 10 days {{or}} [[Famciclovir]] 250 mg PO tid for  at least 10 days {{or}} [[Valacyclovir]] 1 g PO bid for at least 10 days)
::*Note: Dose-adjustment is often necessary among patients with impaired renal function


*Anti-viral therapy:
:*Oral antiviral drugs are indicated within 5 days of the start of the episode and while new lesions are still forming.
:*Antiviral therapy does not alter the natural history of the [[disease]].
:*Topical agents are less effective than oral agents. Combined oral and topical treatment is of no benefit.
:*Intravenous therapy is indicated only when the patient cannot swallow or tolerate oral medication because of vomiting.
:*There is no evidence for benefit from courses longer than five days. However, it may be prudent to review the patient after 5 days and continue therapy if new lesions are still appearing at this time.
{| style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center |{{fontcolor|#FFF|PID TREATMENT}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Acyclovir]] 400 mg po tid x 7-10 days'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Famciclovir]] 250 mg po tid x 7-10 days'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Valacyclovir]] 1000 mg bid x 7-10 days'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen(severe cases)'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Acyclovir]] 5 mg/kg IV q8h x 5–7 days'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen(HSV resistance)'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Foscarnet]] 90 mg/kg IV q12h x 7 days'''''
|-
|}
|}
==Management of Complications==
==Management of Complications==
*Hospitalisation may be required for urinary retention, meningism, and severe constitutional symptoms.
*Hospitalization may be required for [[urinary retention]], [[meningism]], and severe constitutional symptoms.<ref name="pmid26042815">{{cite journal| author=Workowski KA, Bolan GA, Centers for Disease Control and Prevention| title=Sexually transmitted diseases treatment guidelines, 2015. | journal=MMWR Recomm Rep | year= 2015 | volume= 64 | issue= RR-03 | pages= 1-137 | pmid=26042815 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26042815  }} </ref>
 
*If catheterization is required, [[Suprapubic catheter|suprapubic catheterization]] is preferred to reduce the risk of ascending infection and the pain associated with the procedure. Suprapubic catheterization also allows normal micturition to be restored without multiple removals and re-catheterisations.<ref name="pmid26042815">{{cite journal| author=Workowski KA, Bolan GA, Centers for Disease Control and Prevention| title=Sexually transmitted diseases treatment guidelines, 2015. | journal=MMWR Recomm Rep | year= 2015 | volume= 64 | issue= RR-03 | pages= 1-137 | pmid=26042815 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26042815  }} </ref>
*If catheterisation is required, suprapubic catheterisation is preferred to prevent theoretical risk of ascending infection, to reduce the pain associated with the procedure, to allow normal micturition to be restored without multiple removals and re-catheterisations
==References==
==References==
{{reflist|2}}
{{reflist|2}}
[[Category:Primary care]]
{{WH}}
{{WS}}
 
[[Category:Sexually transmitted diseases]]
[[Category:Sexually transmitted diseases]]
[[Category:Viral diseases]]
[[Category:Viral diseases]]
[[Category:Infectious disease]]
[[Category:Gynecology]]
[[Category:Gynecology]]
[[Category:Dermatology]]
[[Category:Dermatology]]
[[Category:Obstetrics]]
[[Category:Obstetrics]]
[[Category:Disease]]
[[Category:Disease]]
 
[[Category:Emergency mdicine]]
{{WH}}
[[Category:Up-To-Date]]
{{WS}}
[[Category:Infectious disease]]
[[Category:Otolaryngology]]
[[Category:Urology]]

Latest revision as of 22:09, 29 July 2020

Sexually transmitted diseases Main Page

Herpes simplex Microchapters

Home

Patient Information

Genital Herpes
Congenital Herpes

Overview

Classification

Orofacial Infection
Anogenital Infection
Ocular Infection
Herpes Encephalitis
Neonatal Herpes
Herpetic Whitlow
Herpes Gladiatorum
Mollaret's Meningitis

Pathophysiology

Epidemiology and Demographics

Asymptomatic Shedding

Recurrences and Triggers

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Direct detection of Genital Lesions

Treatment

Antiviral Therapy

Overview
Antivirals for First Episode of Genital Herpes
Antivirals for Recurrent Genital Herpes

Primary Prevention

Counseling

Herpes simplex genitalis antiviral treatment of first episode genital herpes On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Herpes simplex genitalis antiviral treatment of first episode genital herpes

CDC on Herpes simplex genitalis antiviral treatment of first episode genital herpes

Herpes simplex genitalis antiviral treatment of first episode genital herpes in the news

Blogs on Herpes simplex genitalis antiviral treatment of first episode genital herpes

Directions to Hospitals Treating Herpes simplex

Risk calculators and risk factors for Herpes simplex genitalis antiviral treatment of first episode genital herpes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Yazan Daaboul, M.D., Lakshmi Gopalakrishnan, M.B.B.S.

Overview

All patients with a first-episode genital herpes require antimicrobial therapy. Medical therapies for first-episode genital herpes include either oral acyclovir, oral famciclovir, or oral valacyclovir. Intravenous antiviral agents may be administered among patients with severe first-episode genital herpes.

Medical Therapy

  • All patients with a first-episode genital herpes require antimicrobial therapy.[1]
  • Treatment aims to manage present lesions but not cure the disease or prevent future occurrences.
  • Antiviral chemotherapy offers clinical benefits to the majority of symptomatic patients and is the mainstay of management.
  • Topical therapy with antiviral drugs offers minimal clinical benefit, and its use is discouraged.

First Clinical Episode of Genital Herpes

Symptomatic Management

  • Many patients with first-episode herpes have mild clinical manifestations, but they are often predisposed to developing severe or prolonged symptoms.
  • Symptomatic therapy includes the following:[1]

Antimicrobial Therapy

  • 1. Mild/Moderate genital HSV infection[1]
  • 1.1. First episode of genital herpes
  • Note (1): Treatment can be extended if healing is incomplete after 10 days of therapy
  • Note (2): Dose-adjustment is often necessary among patients with impaired renal function
  • 2. Severe genital HSV infection
  • 2.1. First episode of genital herpes
  • Preferred regimen: Acyclovir 5-10 mg/kg IV q8h for 2-7 days or until clinical improvement THEN (Acyclovir 400 mg PO tid for at least 10 days OR Acyclovir 200 mg PO five times a day for at least 10 days OR Famciclovir 250 mg PO tid for at least 10 days OR Valacyclovir 1 g PO bid for at least 10 days)
  • Note: Dose-adjustment is often necessary among patients with impaired renal function

Management of Complications

  • Hospitalization may be required for urinary retention, meningism, and severe constitutional symptoms.[1]
  • If catheterization is required, suprapubic catheterization is preferred to reduce the risk of ascending infection and the pain associated with the procedure. Suprapubic catheterization also allows normal micturition to be restored without multiple removals and re-catheterisations.[1]

References

  1. 1.0 1.1 1.2 1.3 1.4 Workowski KA, Bolan GA, Centers for Disease Control and Prevention (2015). "Sexually transmitted diseases treatment guidelines, 2015". MMWR Recomm Rep. 64 (RR-03): 1–137. PMID 26042815.

Template:WH Template:WS